vs

Side-by-side financial comparison of IREN Ltd (IREN) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $184.7M, roughly 1.1× IREN Ltd). Ultragenyx Pharmaceutical Inc. runs the higher net margin — -62.0% vs -84.1%, a 22.1% gap on every dollar of revenue. On growth, IREN Ltd posted the faster year-over-year revenue change (59.0% vs 25.9%). Ultragenyx Pharmaceutical Inc. produced more free cash flow last quarter ($-100.8M vs $-468.0M).

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

IREN vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.1× larger
RARE
$207.3M
$184.7M
IREN
Growing faster (revenue YoY)
IREN
IREN
+33.1% gap
IREN
59.0%
25.9%
RARE
Higher net margin
RARE
RARE
22.1% more per $
RARE
-62.0%
-84.1%
IREN
More free cash flow
RARE
RARE
$367.3M more FCF
RARE
$-100.8M
$-468.0M
IREN

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
IREN
IREN
RARE
RARE
Revenue
$184.7M
$207.3M
Net Profit
$-155.4M
$-128.6M
Gross Margin
64.4%
Operating Margin
-63.0%
-54.7%
Net Margin
-84.1%
-62.0%
Revenue YoY
59.0%
25.9%
Net Profit YoY
-610.0%
3.5%
EPS (diluted)
$-0.52
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IREN
IREN
RARE
RARE
Q4 25
$184.7M
$207.3M
Q3 25
$240.3M
$159.9M
Q2 25
$166.5M
Q1 25
$139.3M
Q4 24
$116.1M
$164.6M
Q3 24
$52.8M
$139.5M
Q2 24
$147.0M
Q1 24
$54.3M
$108.8M
Net Profit
IREN
IREN
RARE
RARE
Q4 25
$-155.4M
$-128.6M
Q3 25
$384.6M
$-180.4M
Q2 25
$-115.0M
Q1 25
$-151.1M
Q4 24
$-21.9M
$-133.2M
Q3 24
$-51.7M
$-133.5M
Q2 24
$-131.6M
Q1 24
$8.6M
$-170.7M
Gross Margin
IREN
IREN
RARE
RARE
Q4 25
64.4%
Q3 25
66.4%
Q2 25
Q1 25
Q4 24
72.2%
Q3 24
39.6%
Q2 24
Q1 24
Operating Margin
IREN
IREN
RARE
RARE
Q4 25
-63.0%
-54.7%
Q3 25
-31.8%
-106.9%
Q2 25
-64.8%
Q1 25
-102.6%
Q4 24
14.9%
-74.3%
Q3 24
-89.2%
-94.6%
Q2 24
-79.1%
Q1 24
11.1%
-151.9%
Net Margin
IREN
IREN
RARE
RARE
Q4 25
-84.1%
-62.0%
Q3 25
160.1%
-112.8%
Q2 25
-69.0%
Q1 25
-108.5%
Q4 24
-18.8%
-80.9%
Q3 24
-98.0%
-95.7%
Q2 24
-89.5%
Q1 24
15.9%
-156.8%
EPS (diluted)
IREN
IREN
RARE
RARE
Q4 25
$-0.52
$-1.28
Q3 25
$1.08
$-1.81
Q2 25
$-1.17
Q1 25
$-1.57
Q4 24
$-0.10
$-1.34
Q3 24
$-0.27
$-1.40
Q2 24
$-1.52
Q1 24
$0.00
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IREN
IREN
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$3.3B
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.5B
$-80.0M
Total Assets
$7.0B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IREN
IREN
RARE
RARE
Q4 25
$3.3B
$421.0M
Q3 25
$1.0B
$202.5M
Q2 25
$176.3M
Q1 25
$127.1M
Q4 24
$427.3M
$174.0M
Q3 24
$98.6M
$150.6M
Q2 24
$480.7M
Q1 24
$259.7M
$112.3M
Stockholders' Equity
IREN
IREN
RARE
RARE
Q4 25
$2.5B
$-80.0M
Q3 25
$2.9B
$9.2M
Q2 25
$151.3M
Q1 25
$144.2M
Q4 24
$1.2B
$255.0M
Q3 24
$1.1B
$346.8M
Q2 24
$432.4M
Q1 24
$677.2M
$140.3M
Total Assets
IREN
IREN
RARE
RARE
Q4 25
$7.0B
$1.5B
Q3 25
$4.3B
$1.2B
Q2 25
$1.3B
Q1 25
$1.3B
Q4 24
$1.9B
$1.5B
Q3 24
$1.3B
$1.5B
Q2 24
$1.6B
Q1 24
$723.6M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IREN
IREN
RARE
RARE
Operating Cash FlowLast quarter
$71.7M
$-99.8M
Free Cash FlowOCF − Capex
$-468.0M
$-100.8M
FCF MarginFCF / Revenue
-253.4%
-48.6%
Capex IntensityCapex / Revenue
292.2%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-701.2M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IREN
IREN
RARE
RARE
Q4 25
$71.7M
$-99.8M
Q3 25
$142.4M
$-91.4M
Q2 25
$-108.3M
Q1 25
$-166.5M
Q4 24
$53.6M
$-79.3M
Q3 24
$-3.9M
$-67.0M
Q2 24
$-77.0M
Q1 24
$-27.1M
$-190.7M
Free Cash Flow
IREN
IREN
RARE
RARE
Q4 25
$-468.0M
$-100.8M
Q3 25
$-38.0M
$-92.7M
Q2 25
$-110.7M
Q1 25
$-167.8M
Q4 24
$-85.5M
$-79.5M
Q3 24
$-109.7M
$-68.6M
Q2 24
$-79.0M
Q1 24
$-108.3M
$-193.9M
FCF Margin
IREN
IREN
RARE
RARE
Q4 25
-253.4%
-48.6%
Q3 25
-15.8%
-58.0%
Q2 25
-66.5%
Q1 25
-120.5%
Q4 24
-73.6%
-48.3%
Q3 24
-208.0%
-49.2%
Q2 24
-53.7%
Q1 24
-199.4%
-178.2%
Capex Intensity
IREN
IREN
RARE
RARE
Q4 25
292.2%
0.5%
Q3 25
75.0%
0.8%
Q2 25
1.5%
Q1 25
1.0%
Q4 24
119.7%
0.1%
Q3 24
200.6%
1.2%
Q2 24
1.4%
Q1 24
149.5%
3.0%
Cash Conversion
IREN
IREN
RARE
RARE
Q4 25
Q3 25
0.37×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-3.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IREN
IREN

Bitcoin Mining Revenue$167.4M91%
AI Cloud Services$17.3M9%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons